

## Policy and Procedure

<b>PHARMACY PRIOR AUTHORIZATION POLICY AND CRITERIA ORPTCCNS064.1025</b>	<b>CENTRAL NERVOUS SYSTEM DRUGS MEDICALLY ADMINISTERED MULTIPLE SCLEROSIS AGENTS</b> See <a href="#">Table 1</a> for Applicable Medications
<b>Effective Date: 1/1/2026</b>	<b>Review/Revised Date:</b> 07/24, 05/25, 09/25 (JEF)
<b>Original Effective Date: 11/23</b>	<b>P&amp;T Committee Meeting Date:</b> 08/23, 08/24, 06/25, 08/25, 10/25
<b>Approved by: Oregon Region Pharmacy and Therapeutics Committee</b>	

### SCOPE:

Providence Health Plan and Providence Health Assurance as applicable (referred to individually as “Company” and collectively as “Companies”).

### APPLIES TO:

Commercial  
Medicaid

### POLICY CRITERIA:

#### COVERED USES:

All Food and Drug Administration (FDA)-Approved Indications

#### REQUIRED MEDICAL INFORMATION:

For **initiation of therapy** for multiple sclerosis (MS), all the following criteria (1-2) must be met:

1. Must have one of the following confirmed diagnoses:
  - a. Relapsing-remitting multiple sclerosis (RRMS)
  - b. Secondary progressive multiple sclerosis (SPMS)
  - c. Clinically isolated syndrome (CIS)
  - d. For Ocrevus only: Primary progressive MS
2. Documentation of ONE of the following (a-d) for RRMS, SPMS, CIS:
  - a. Documentation the patient has highly active disease defined as ONE of the following:
    - i. Greater than or equal to two relapses in the previous year
    - ii. The patient has greater than or equal to one gadolinium enhancing lesion on MRI
    - iii. Presence of significant T2 lesion burden defined as ONE of the following:
      - 1) Greater than ten (10) T2 lesion burden as documented with MRI
      - 2) Significant increase in T2 lesion load compared with a previous MRI

**PHARMACY PRIOR AUTHORIZATION  
POLICY AND CRITERIA  
ORPTCCNS064**

**CENTRAL NERVOUS SYSTEM DRUGS  
MEDICALLY ADMINISTERED MULTIPLE  
SCLEROSIS AGENTS**

See [Table 1](#) for Applicable Medications

- 3) T2 lesion(s) located in spinal cord or brainstem
  - b. The patient has been treated with at least three multiple sclerosis agents from different drug classes
  - c. Inadequate response (after at least six months of continuous therapy) or intolerance to one of the following: generic dimethyl fumarate, generic glatiramer/Glatopa®, generic fingolimod, or generic teriflunomide
  - d. FDA labeled contraindication to ALL the following: generic dimethyl fumarate, generic glatiramer/Glatopa®, generic fingolimod, and generic teriflunomide
3. For Ocrevus Zunovo®: Documentation of appropriate medical rationale for using this product over Ocrevus IV®

For **patients established on therapy** for at least three months, the following must be met (Note: Medications obtained as samples, coupons, or any other method of obtaining medications outside of an established health plan benefit are NOT considered established on therapy): Documentation of positive clinical response to therapy

**EXCLUSION CRITERIA:**

Concurrent use with other disease modifying agents for multiple sclerosis

**AGE RESTRICTIONS:** N/A

**PRESCRIBER RESTRICTIONS:**

Must be prescribed by or in consultation with a neurologist.

**COVERAGE DURATION:**

Initial authorization will be approved for one year. Reauthorization will be approved until no longer eligible with the plan, subject to formulary and/or benefit changes

---

*Requests for indications that were approved by the FDA within the previous six (6) months may not have been reviewed by the health plan for safety and effectiveness and inclusion on this policy document. These requests will be reviewed using the New Drug and or Indication Awaiting P&T Review; Prior Authorization Request ORPTCOPS047*

*Requests for a non-FDA approved (off-label) indication requires the proposed indication be listed in either the American Hospital Formulary System (AHFS), Drugdex, or the National Comprehensive Cancer Network (NCCN) and is considered subject to evaluation of the prescriber's medical rationale, formulary alternatives, the available published evidence-based research and whether the proposed use is determined to be experimental/investigational.*

*Coverage for Medicaid is limited to a condition that has been designated a covered line item number by the Oregon Health Services Commission listed on the Prioritized List of Health Care Services.*

**PHARMACY PRIOR AUTHORIZATION  
POLICY AND CRITERIA  
ORPTCCNS064**

**CENTRAL NERVOUS SYSTEM DRUGS  
MEDICALLY ADMINISTERED MULTIPLE  
SCLEROSIS AGENTS**

See [Table 1](#) for Applicable Medications

*Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case*

**INTRODUCTION:**

Ublituximab-xiyy (Briumvi®), a B-cell therapy with CD20-directed cytolytic monoclonal antibody for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Ublituximab-xiyy is administered every 24 weeks (six months).

Ocrelizumab (Ocrevus®), a B-cell therapy with CD20-directed cytolytic monoclonal antibody for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults, and primary progressive MS in adults.

**FDA APPROVED INDICATIONS:**

**Table 1.** Medically infused multiple sclerosis medications

Drug	Class	RRMS	SPMS	CIS	PPMS
ublituximab (Briumvi®)	Recombinant monoclonal antibody, binds to CD52, natural killer cells, monocytes, and macrophages	X	X	X	
ocrelizumab/hyaluronidase (Ocrevus Zunovo®)	Immune modulator, binds to CD-20	X	X	X	X
ocrelizumab (Ocrevus®)	Immune modulator, binds to CD-20	X	X	X	X

*MOA = mechanism of action, RRMS = relapsing-remitting multiple sclerosis, SPMS = secondary progressive multiple sclerosis, CIS = clinically isolated syndrome; PPMS: primary progressive multiple sclerosis*

**POSITION STATEMENT:**

Guidelines for Multiple Sclerosis include the American Academy of Neurology Publication “Comprehensive Systematic Review Summary: Disease-Modifying Therapies for Adults with Multiple Sclerosis” published in 2018 and a consensus paper by the Multiple Sclerosis Coalition titled “The Use of Disease-Modifying Therapies in Multiple Sclerosis” published in 2019. Guidelines state that initiating a disease modifying therapy (DMT) should be offered to patients as early as possible.

**PHARMACY PRIOR AUTHORIZATION  
POLICY AND CRITERIA  
ORPTCCNS064**

**CENTRAL NERVOUS SYSTEM DRUGS  
MEDICALLY ADMINISTERED MULTIPLE  
SCLEROSIS AGENTS**

See [Table 1](#) for Applicable Medications

The choice of initial DMT should be individualized to consider safety, route of administration, lifestyle, cost, efficacy, adverse effects (AEs), and tolerability. When switching therapies after failure of an agent, disease activity, adherence, AE profiles, and mechanisms of action should be considered when selecting a new agent to start. For advanced, aggressive, or highly active disease guidelines recommend fingolimod (Gilenya®), natalizumab (Tysabri®), ocrelizumab (Ocrevus®), or alemtuzumab (Lemtrada®). Additionally, guidelines state categorize DMT therapies for evidence for lowering relapse rate (see Table 2).<sup>3</sup>

**Table 2. DMT Evidence for Lowering Relapse Rate<sup>3</sup>**

Very Low	Low	Moderate	Strong
Immunoglobulins	Cyclophosphamide	Azathioprine	Alemtuzumab
Methotrexate	Mycophenolate Mofetil	Interferon beta-1b	Cladribine
Rituximab			Dimethyl Fumarate <sup>†</sup>
Corticosteroids			Fingolimod <sup>†</sup>
			Glatiramer Acetate <sup>†</sup>
			Interferon beta-1a
			Mitoxantrone
			Natalizumab
			Ocrelizumab
			Pegylated Interferon
			Teriflunomide <sup>†</sup>

<sup>†</sup> Generic Available

**Table 3. BILLING GUIDELINES AND CODING:**

DRUG CODES*		
J2329	Injection, ublituximab-xiiy, 1mg	Briumvi®
J2350	Injection, ocrelizumab, 1 mg	Ocrevus®
J2351	Injection, ocrelizumab, 1 mg and hyaluronidase-ocsq	Ocrevus Zunovo®
ADMINISTRATION CODES		
96365	Ther/proph/diag iv inf init	
96366	Ther/proph/diag iv inf addon	

**PHARMACY PRIOR AUTHORIZATION  
POLICY AND CRITERIA  
ORPTCCNS064**

**CENTRAL NERVOUS SYSTEM DRUGS  
MEDICALLY ADMINISTERED MULTIPLE  
SCLEROSIS AGENTS**

See [Table 1](#) for Applicable Medications

96372	Ther/proph/diag inj sc/im	
96401	Chemo anti-neopl sq/im	
96413	Chemo iv infusion 1 hr	
93415	Chemo iv infusion addl hr	
<b>MODIFIER CODES†</b>		
-JA	Administered Intravenously	
-JB	Administered Subcutaneously	
-JW	Drug Amount Discarded/Not Administered to Any Patient	
-JZ	Zero drug amount discarded/Not administered to Any Patient	

\*Coding Notes:

- The above code list is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit.

- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

†Must be billed with the JA modifier for the intravenous infusion of the drug or billed with the JB modifier for the subcutaneous injection form of administration Discarded Drugs and Biologicals – [JW Modifier and JZ Modifier Policy FAQ](#)

**REFERENCE/RESOURCES:**

1. Relevant package inserts
2. DRUGDEX® System [Internet database]. Greenwood Village, Colo: Thomson Reuters (Healthcare) Inc. Updated periodically.
3. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis. *Neurology* 2018;90:777–788.